Changing the landscape in
Life-Threatening Diseases

At Reata Pharmaceuticals, our mission is to develop innovative therapies that change patients’ lives for the better.

Our Pipeline

Reata’s development programs have created a robust pipeline of drug candidates for the treatment of serious, life-threatening diseases. Find out more here.

Phase 1
Phase 2
Regulatory Review
Friedreich's Ataxia | Omaveloxolone Friedreich's Ataxia
RTA 901
Chronic Kidney Disease
CKDb Caused by Alport Syndrome | Bardoxolonec CKD Caused by Alport Syndrome
CKD Caused by ADPKDd | Bardoxolone CKD Caused by ADPKD
Type 1 and Type 2 Diabetes and Advanced CKD | Bardoxolonee Type 1 and Type 2 Diabetes
and Advanced CKD

aDiabetic peripheral neuropathic pain (DPNP). bChronic Kidney Disease (CKD). cBardoxolone methyl (bardoxolone). On February 25, 2022, we received a Complete Response Letter from the Food and Drug Administration (FDA). We will continue to work with the FDA to confirm our next steps on our Alport syndrome program. Marketing Authorisation Application in Europe is under review. dAutosomal Dominant Polycystic Kidney Disease (ADPKD). eAYAME study conducted in Japan by our strategic collaborator in CKD, Kyowa Kirin. Kyowa Kirin expects the last patient out in the second half of 2022.

Omaveloxolone, bardoxolone methyl, and RTA 901 are investigational drugs. Safety and efficacy have not been established by any agency.

image oval image oval2

Latest News

More News


We are a team of problem solvers, trailblazers, and people who want to make a difference.

Learn More
Dawn of a New Era